Starting Dose of Lokelma for CKD Patients Not on Dialysis
For CKD patients not on dialysis with hyperkalemia, start Lokelma at 10 g three times daily for up to 48 hours, then transition to 10 g once daily for maintenance. 1
Initial Treatment Phase (Correction Phase)
The FDA-approved dosing regimen is straightforward:
- 10 g orally three times daily for up to 48 hours
- Mix each dose in approximately 3 tablespoons of water
- Continue until normokalemia is achieved (potassium 3.5-5.0 mEq/L)
This dosing is supported by robust clinical trial data showing that 98% of patients achieve normokalemia within 48 hours using this regimen 2. The onset of action begins within 1 hour, with significant reductions in serum potassium observed by 2 hours 3.
Maintenance Phase
After achieving normokalemia:
- Start at 10 g once daily 1
- Monitor serum potassium levels regularly
- Adjust dose in 5 g increments at intervals of 1 week or longer
- Maintenance dose range: 5 g every other day to 15 g daily
Important distinction: This patient is NOT on dialysis, so do not use the hemodialysis dosing protocol (which starts at 5 g on non-dialysis days) 1.
Clinical Evidence Supporting This Approach
The HARMONIZE trial demonstrated that 10 g three times daily rapidly corrected hyperkalemia, with median time to normalization of 2.2 hours 4. In the 12-month open-label study, this approach maintained normokalemia in 88% of patients during months 3-12, with a mean daily maintenance dose of 7.2 g 2.
Importantly, 82-90% of CKD patients maintained normokalemia throughout 12 months regardless of baseline eGFR, including those with severe CKD (eGFR <30 mL/min/1.73 m²) 5.
Key Practical Considerations
Timing with other medications: Administer other oral medications at least 2 hours before or after Lokelma to avoid binding interactions 1.
Sodium content: Each 5 g dose contains approximately 400 mg of sodium. Monitor for edema, particularly in patients with heart failure or those who should restrict sodium intake 1. In clinical trials, edema was generally mild to moderate and more common with the 15 g daily dose 3.
Monitoring strategy:
- Check potassium levels after 48 hours of initial treatment
- During maintenance, monitor at 1-week intervals after dose adjustments
- Watch for hypokalemia (occurred in 10-11% at higher maintenance doses) 4
- Consider checking bicarbonate levels, as SZC sustainably increases serum bicarbonate, which may benefit patients with metabolic acidosis 3
Common Pitfalls to Avoid
Do not use Lokelma for emergency treatment of life-threatening hyperkalemia due to delayed onset compared to insulin/glucose or dialysis 1
Avoid in patients with severe constipation or bowel obstruction, as it has not been studied in these populations and may worsen gastrointestinal conditions 1
Do not confuse with hemodialysis dosing: The 5 g starting dose is only for patients on chronic hemodialysis, not for CKD patients not on dialysis 1
Do not underdose initially: The 10 g three times daily regimen is necessary for rapid correction; starting with maintenance dosing will delay potassium normalization
Additional Benefits
Beyond potassium control, Lokelma enables continuation and optimization of RAAS inhibitor therapy in 87% of patients, with 14% of RAAS-naïve patients able to initiate these cardioprotective medications 2. This is particularly important for CKD patients who benefit from RAAS inhibition but are often limited by hyperkalemia risk 3, 6.
The safety profile is favorable, with no serious adverse events attributed to the medication in randomized trials 3. The most common adverse events are mild gastrointestinal symptoms and dose-dependent edema 1.